The European REACH regulation places responsibility for providing safety information, including Derived No-Effect Levels (DNELs), on chemicals and chemical products on "industry", i.e. manufacturers and importers. We compared long-term inhalation workerDNELs (wDNELs) presented by industry with the corresponding Swedish OELs, and for a subset, with wDNELs derived by us. Our wDNELs were derived using toxicological evaluations published by the Swedish Criteria Group and our interpretation of the REACH Guidance. On average, industry's wDNELs were the same as the Swedish OELs (median of wDNEL-OEL ratios 0.98, n=235). However, the variation was huge, the extremes being up to 450 times higher and up to 230 times lower than the corresponding OEL. Nearly one fifth of the wDNELs were ≥2 times higher and one third ≥2 times lower than the OEL. No time trend was seen in the wDNEL/OEL ratios, suggesting that older OELs were not systematically higher than the more recent ones. Industry's wDNELs varied widely and were generally higher (median 4.2 times, up to 435 times higher, down to 13 times lower, n=23) also compared to our wDNELs. Only five industry wDNELs were equal to or lower than ours. The choices of key studies, dose descriptors and assessment factors all seemed to contribute to the discrepancies. We conclude that, although the REACH guidance is detailed, many choices that will influence the wDNEL lack firm instructions. A major problem is that little advice is given on when and how to depart from default assessment factors.
INTRODUCTION
The European Union (EU) chemicals legislation called REACH came into force in June 2007. REACH stands for Registration, Evaluation, Authorisation and Restriction of Chemical substances. The most important aims of the REACH system are to improve protection of human health and environment from the risks of chemicals, and to enhance innovation and competitiveness of the EU chemicals industry (European Commission, 2006) .
The REACH regulation places greater responsibility on industry to manage the risks from chemicals and to provide safety information on the substances. Manufacturers, importers and downstream users should ensure that they manufacture, place on the market or use substances in such a way that they do not adversely affect human health. To this end, a chemical safety assessment (CSA) has to be performed by registrants for substances manufactured and/or imported in amounts greater than 10 tons per year. The CSA includes assessments of hazard and exposure, and should derive exposure scenarios for all supported uses. This CSA is to be documented in a chemical safety report (CSR) and submitted to the European Chemicals Agency (ECHA), based in Helsinki (European Commission, 2006) . The agency acts as a central point in the REACH system as it manages the databases necessary to operate the system, co-ordinates the in-depth evaluation of chemicals of special concern and builds a public dissemination database in which consumers and professionals can find hazard information (http://echa.europa.eu, 2014-04-11).
As a step in the risk assessment of chemicals, the so called derived no effect level (DNEL) is to be derived for the CSA for substances with identifiable threshold effects. The DNEL is an exposure level that should represent "the level of exposure above which humans should not be exposed" (article 1.0.1, European Commission 2006). The DNELs thus play a crucial role in the REACH CSA, serving as a benchmark value. The DNELs must address acute and repeated exposure, different exposure routes (such as inhalation or skin contact), differentiate between systemic and local effects, and also between workplace and general population exposure as appropriate for the intended use pattern. Thus, several DNELs may be defined for each individual compound (ECHA, 2012) .
The REACH guidance on "information requirements and chemical safety assessment" (ECHA, 2012) gives advice on methodical approaches for the derivation of DNELs. Thus, this guidance gives the different steps involved in this process and the aspects needed to be considered. The DNEL that the registrant derives will depend upon the selected dose descriptors and the assessment factors (AFs) applied for extrapolation from animal data to man. In most cases the dose descriptor(s) is a No Observed Adverse Effect Level (NOAEL) or a Lowest Observed Adverse Effect Level (LOAEL), but might also be a different measure such as a benchmark dose. When the dose descriptor is not directly comparable to the target exposure route of the DNEL, it is modified to provide a correct starting point. The DNEL is then calculated by dividing the (modified) dose descriptor by a series of AFs. These AFs are numerical values that take into account the variability and uncertainty when extrapolations of animal data are made (ECHA). The last step of this process consists of selecting the leading health effect and the corresponding most critical DNEL for the relevant exposure pattern. This critical DNEL should be the lowest obtained for each exposure pattern (ECHA, 2012; R.8.7 Step 4). The DNELs registered by industry are made publicly available through the ECHA database on registered substances available at http://echa.europa.eu/information-onchemicals/registered-substances (2014-04-11) , and henceforth referred to as the ECHA database.
The aim of this study was to examine how worker-DNELs have been derived under the REACH regulation. Previous similar investigations of DNELs preceded the first registration deadline, at which time industry-derived DNELs were not available (Schenk and Johanson, 2011; Kreider and Williams, 2010) . These early investigations noted that adherence to default AFs given in the REACH guidance would lead to DNEL values significantly lower than previously established limits, such as the European Union Indicative Occupational Exposure Limit Values (EU IOELV). As there are now more than 10,000 substances registered, and some 3200 have one or several long-term worker-DNELs for the inhalation route (GESTIS DNEL database last updated in April 2014, http://www.dguv.de/ifa/Gefahrstoffdatenbanken/GESTIS-DNEL-Datenbank/index-2.jspm, accessed on July 30th 2014), it is now possible to compare the "real-life" outcome with that predicted from the REACH guidance document. Nies et al. (2013) compared the registered long-term worker-DNELs for the inhalation route, available in mid-2012, with the German statutory OELs (AGW), the German MAK commissions' recommendations and the EU IOELVs. Compared to the EU IOELVs 75% of the worker-DNELs were identical, while compared to the MAK-and AGW values some 40% were identical. Roughly equal shares of the DNELs were lower and higher than the OELs (Nies et al., 2013) .
To facilitate comparisons and to make use of consistent toxicological reviews we limited our deliberations to worker-DNELs for the inhalation route and long-term exposure (wDNELs). These DNELs have some resemblance with Occupational Exposure Limits (OELs) as they both address airborne exposure and aim to protect workers' health. Their resemblance is further strengthened by the statement in the REACH guidance that registrants are allowed to use a health-based OEL as a DNEL for the same exposure route and duration, unless it is contradicted by new scientific information.
In the present study we derived DNELs for a selection of chemical substances by applying the REACH guidance document to (modified) dose descriptors identified in the toxicological evaluations performed by the Swedish Criteria Group (SCG). The resulting DNELs (our wDNELs) were then compared with those derived by the registrants (industry wDNELs) and with the Swedish OELs.
METHODS
The DNELs most comparable to OELs, and hence of relevance for the present study, are those set to protect workers from long-term adverse effects caused by inhalation of the substance. The full label for these DNELs is "worker-DNEL long-term for inhalation route-systemic" or, if the effect is local, "worker-DNEL long-term for inhalation route-local", both henceforth referred to as wDNELs. As a first step, the Swedish list of OELs (8-h time-weighted averages, SWEA, 2011) was compared to the registered wDNELs (ECHA database accessed on October 30 th 2013). In the case where the registrant had derived different wDNELs for local and systemic effects, the lower value of the two was chosen. As a second step we derived our own wDNELs for a selection of substances. The procedure is schematically outlined in Figure  1 , and described in some more detail in the following sections.
[ Figure 1 ] Source of data and selection of substances For the present study toxicological evaluations performed by the SCG are used as a scientific basis for the wDNELs derived by us. The SCG consists of experts in toxicology, chemistry, occupational hygiene and medicine, external university professors and scientific experts (www.av.se/teman/hygieniska_gransvarden/kriteriegruppen/, 2014-04-11). This group gathers and evaluates data on health effects relevant for the work environment. The SCG also prepares a consensus report summarizing toxicological and medical data; in which doseeffect/dose-response relationships are discussed, the critical effect is defined and relevant NOAELs or LOAELs are identified. The SCG documents are published both in Swedish and English in the serial Arbete och Hälsa (available through https://gupea.ub.gu.se/handle/2077/3194, 2014-04-11). The reason for choosing this set of documents is that the SCG merely presents the key toxicological data and does not suggest OELs, present assessment factors or give any other quantitative guidance on uncertainties. For the purpose of the present study all SCG documents published between 1998 and 2012 were searched for CAS registry numbers and adhering critical effects. This resulted in close to 230 individual substances, in 73 separate evaluations. Substances (a) not found in in the ECHA database, (b) lacking a wDNEL in the ECHA database were excluded. Furthermore, we excluded substances (c) for which the EU IOELV was equal to the wDNEL as the registrants may, under certain conditions, use the IOELV in place of developing a wDNEL de novo (ECHA 2012). We did not control national OELs as replacers as this alternative approach is associated with stricter requirements (ECHA 2012). Finally, we excluded substances (d) for which a DNEL would be unsuitable according to the guidance document (e.g. respiratory sensitisers and direct-acting genotoxic carcinogens) or (e) the SCG document did not contain suitable data to derive a DNEL. Respiratory sensitisers were identified through their classification and labelling. As mode of action (threshold or non-threshold) was frequently not evaluated by the SCG, all substances which had carcinogenicity as the critical effect in the SCG document were excluded. In total 35 substances, evaluated in 19 different documents fulfilled the selection criteria (Figure 1 ). The SCG documents used in the present study were published in the following volumes: Lundberg (1998), Montelius (1999; 2000; 2001; 2003; 2005a; b; 2009; 2010; 2013) .
Identification of relevant dose descriptors
Dose descriptors relevant for the occupational setting were identified by close reading of the SCG reports. It should be noted that the SCG, as many other OEL-setting groups, gives more weight to human data than to animal data when selecting critical effect and the corresponding dose descriptors. However, in this first step we selected data for as many different effects (end points) as possible. Apart from the dose descriptor, additional information about the study is needed to derive the wDNELs. Hence, for each effect we extracted information about the identified effect, LOAEL or NOAEL, tested species and exposure conditions from the SCG summary reports. In addition, the publication year of the study was extracted. In the few cases were the SCG document did not include information on the above details, we accessed the original publication.
Modifying the dose descriptors
The dose descriptors were then adjusted according to the guidelines on adjustment of the dose descriptor in REACH guidance (ECHA, 2012) . The aspects considered are briefly described in the following sections.
Route to route extrapolation
The wDNEL addresses human inhalation exposure. If the dose descriptor is from a different exposure route (e.g. oral or dermal) a route extrapolation has to be performed. A default factor of 2 is recommended in the guidance document to account for differences in absorption between different routes, thus assuming 50% absorption by the tested exposure route and 100% absorption by inhalation. As with the other default factors, this factor can be set to other values if supported by empirical data. Other default assumptions are a body weight of 70 kg and a lung ventilation volume of 10 m³ during an 8-h work shift.
Allometric scaling
Allometric scaling accounts for differences in metabolic rate between species of different size. If the dose descriptor is from an oral or dermal study, different adjustment factors are required depending on the species, e.g. dog 1.4, rabbit 2.4 and rat 4. No allometric scaling is needed if the dose descriptor is from an inhalation study and the bioavailability can be assumed to be equal in humans and the tested species (Table R. 8-3 in ECHA, 2012) .
Correction for exposure conditions
For dose driven effects and experimental settings where the exposures differ from the usual 8h/day the dose descriptor should be corrected using Haber's law: C n × t = k, where C denotes the concentration, t the duration of exposure and k is a constant. Unless chemical-specific data tells otherwise, n=1 is used when adjusting from shorter to longer exposure, for instance from 6h/day to 8h/day, whereas n=3 is used when adjusting in the opposite directions, for instance from continuous exposure to 8h/day, 5 days/week. Local irritation effects were, unless data in the SCG document specified otherwise, assumed to be concentration driven. Hence such dose descriptors were not corrected for exposure duration.
Correction for differences in respiratory volume
The default lung ventilation during an 8h work shift is 10m³ for workers with light physical activity. For humans without activity the default in the REACH guidance (ECHA, 2012) is 6.7m³ per 8h.
Derivation of REACH assessment factors

Additional interspecies differences
If no substance-specific data are available, the default procedure is to correct for differences in metabolic rate as above and then apply an additional factor of 2.5 to account for other toxicokinetic differences not related to metabolic rate (small part) as well as toxicodynamic differences (larger part). If the critical effect is local, located elsewhere than the respiratory tract and does not require metabolism of the substance in question, a factor of 1 is used. For local effects in the respiratory tract the factor of 2.5 remains.
Intraspecies differences
As workers are a subgroup of the population (more healthy and excluding the very young and very old) for which a smaller intraspecies variability is expected. Thus, a factor of 5 is recommended for intraspecies extrapolation for workers, in contrast to the factor 10 given for the general population.
Differences in exposure duration
Longer exposure durations can generally be expected to result in more frequent and/or more severe toxic effects and hence lead to lower NOAELs and LOAELs. Table R.8-5 in the REACH guidance (ECHA, 2012) lists AFs addressing differences in exposure duration. A factor of 6 is set for extrapolation from sub-acute (28 days) to chronic (1.5-2 years). This factor can be divided in factors of 3 for sub-acute to sub-chronic (90 days) and 2 for subchronic to chronic extrapolations. No recommendations are given for extrapolation of acute exposure data (less than 8h) to chronic exposure (as with wDNELs).
Issues related to dose-response
Several aspects of the dose-response relationship fall under this heading. If the wDNEL is derived from a LOAEL instead of a NOAEL an AF of 3 is recommended in the majority of cases, but also it is mentioned that it might be suitable with higher factors (up to 10). No specific advice on magnitude of the AF is given for such cases. For the purpose of the present study we have applied an AF of 3 for all extrapolations from LOAEL to NOAEL. No consideration was given to the slope of the dose-response curve when determining AFs.
Quality of the database
Issues with the quality of the whole database, not covered by the previous aspects, may justify an additional AF, for instance if data are contradictory or lacking. However, the default recommendation is 1; this recommendation was followed for all substances in the present study.
Selecting the most critical DNEL
Subsequent to the assignment of individual AFs for each relevant study according to the above schemes, an overall assessment factor (OAF) was calculated by multiplying the individual AFs. Secondly, temporary DNELs were calculated by dividing each (modified) dose descriptor by the corresponding OAF. The lowest DNEL, i.e. the most critical DNEL (ECHA, 2012), for each substance was chosen as the final DNEL. The corresponding effect is called the leading effect (ECHA, 2012) . This approach often, but not always, resulted in different leading effects for our wDNELs than the critical effects identified by the SCG. In some cases our leading dose descriptor (from animal data) was higher than the one corresponding to the critical effect in humans identified by the SCG. Yet, as the extrapolation from animal data includes more uncertainties, resulting in higher AFs, the ensuing wDNEL was lower than had the SCG critical dose descriptor (from human data) been selected.
Tracing the registrants' DNEL derivation process
Differences between our wDNELs and those of the registrants may be caused not only by different choices of AFs but also different opinions -or time-related availability -on the choice of critical study resulting in different modified dose descriptors (MDD). In order to be able to compare the choice of AFs without being obscured by different MDDs, we also attempted to identify the dose descriptors used by registrants for their wDNEL derivations. In many of the dossiers the starting point dose descriptor was obvious, in such cases we assumed that the registrants' wDNEL was based on a dose descriptor concerning the most sensitive endpoint. This information was listed in the DNEL related information in the ECHA database for all but three of the included wDNELs (accessed 2014-04-11). For the substances included in the present study the most sensitive endpoints listed were either "repeated dose toxicity" (RDT), Irritation respiratory tract (IRT), Skin irritation/corrosion (SIrCo) or "developmental toxicity / teratogenicity" (Dev/Ter). Unless specified in the DNEL related information, it was further assumed that the wDNELs were primarily based on dose descriptors from inhalation studies also identified as key studies. If no such inhalation key study was listed, dose descriptors from an oral study labelled key study or inhalation weight of evidence were collected. It should be noted that the actual key dose descriptor used for the derivation of DNELs is not necessarily publicly disseminated. An example would be when the registered wDNEL is based on a health-based OEL, which may or may not be disseminated in the DNEL related information.
For those substances were several dose descriptors seemed to equally fulfil the criteria, preference was given to NOAELs over LOAELs and to higher NOAELs over lower NOAELs as long as they were lower than a LOAEL from any other study reported by the registrant. Likewise, lower LOAELs were preferred over higher LOAELs. In case of sex differences, the dose descriptor based on the more sensitive sex was selected. For dose descriptors derived by read across we recalculated the mass assuming that critical doses are equivalent on a molar basis.
If the most sensitive endpoint was not identified in the DNEL related information we assumed that the DNEL is based on a repeated dose study for the inhalation route. From this assumption we followed the same procedure as described above.
If more than one study or publication was referred to in the section of data source, the earliest and presumably original one was selected for comparing the age of dose descriptors. If both a study period and publication year was given and these differed the publication year was selected for tabulation.
If specified in the ECHA database, industry's OAFs were compared to the default OAF. The default OAF was calculated by us according to the same procedure as described in the section "Derivation of REACH assessment factors".
RESULTS
Industry wDNELs registered in the ECHA database, were compared with the corresponding Swedish 8-h OELs, an overview of this comparison is presented in the bottom panel of Figure  2 . Acute/short-term wDNELs were not considered, as we were unable to ascertain the exposure duration. The ECHA guidance document only suggests 15 min as relevant in most cases for the occupational setting, but actual duration is not specified in the DNEL related information. Almost 240 substances with a Swedish 8-h OEL also had one or several registered wDNELs, for 17 substances different registrants had derived divergent wDNELs. A potential confounder of these comparisons is the fact that for particulates the size fraction is specified in the Swedish list of OELs but not in the DNEL related information found in the ECHA database.
[ Figure 2 ] Comparing the Swedish OELs and registered wDNELs, the most extreme differences were found for 2-ethoxyethanol and 1,1,1-trifluoroethane. For the former the Swedish OEL is 19 mg/m 3 while the registered wDNEL is 0.083 mg/m 3 , i.e. 230 times lower. For the latter the Swedish OEL is 1750 mg/m 3 while the registered wDNEL is 38800 mg/m 3 , i.e. 450 times higher. Including the lowest wDNEL for the 17 substances with several DNELs from different registrants, 25 wDNELs are identical to the Swedish OEL (including the highest instead results in 22 identical limits). As can be seen in Figure 2 , many wDNELs are lower than the Swedish OEL. However, there is a wide spread and nearly one fifth of the wDNELs are at least double the Swedish OEL, whereas one third of the wDNELs are half the value of lower. As Swedish OELs are set in a much larger time span (1974 to 2011) than the wDNELs (the first REACH registration deadline was in 2010), part of the variation could be expected to be due to time. However, plotting the ratios between wDNEL and Swedish OEL over the year of the Swedish OELs yields a rather uniform distribution (Figure 3) . The variation that would be explained by year of Swedish OEL is about 1% (r 2 =0.009, linear regression on logarithm of ratio).
[ Figure 3 ] For the 20 substances fulfilling our selection criteria an overview of how our wDNELs were derived is presented in Table 1 and Table 2 . In Table 1 the conclusions from the SCG are presented first followed by the effect and dose descriptor selected from the same document for our leading wDNEL. In Table 2 we present the modification of the dose descriptor and selection of AFs. Our OAFs ranged from 1 to 225.
[ Table 1 ] [ Table 2 ] Table 3 lists the wDNELs registered by industry, the corresponding Swedish OELs and the wDNELs derived by us. Also this sub selection displays a large variability when comparing the Swedish OELs with industry wDNELs (Figure 2 , middle panel). Comparing our wDNELs with industry's yields a similar range, but moved to the right as our wDNELs are generally lower than both the Swedish OELs (16 out of 18) and industry's wDNELs (18 out of 23). The difference between the industry wDNEL and our wDNEL ranged from 13 times lower to 435 times higher (median 4.2 times higher). Five of the industry wDNELs were equal to or lower than ours, including the lower among the registered wDNELs for n-butyl acetate. For four substances industry's wDNELs were more than 10 times higher than our wDNELs (Figure 2 , upper panel).
[ Table 3 ] Among the 20 substances there are four pairs of structurally related compounds: odichlorobenzene/p-dichlorobenzene, diethylamine/dimethylamine, ethanolamine/triethanolamine and isopentyl acetate/n-butyl acetate. We found no systematic pattern in the magnitude of the differences between registrants' and our wDNELs within these four groups. As an example, the registrants' wDNEL for o-dichlorobenzene is 4.2 times higher than our wDNEL; for p-dichlorobenzene the registered wDNEL is 8.8 times higher. Neither did we find a systematic pattern within each pair for registrants' wDNELs, Swedish OELs or our wDNELs, with the possible exception of isopentyl acetate and the lower of the registered wDNELs for n-butyl acetate. The ratio of these wDNELs is 2.3, which is relatively similar (1.25 times higher) to the corresponding ratios for Swedish OELs (1.9) and our wDNELs (1.9). For the other substance pairs the ratios are significantly further apart; the highest ratio is 2.6 to 12.5 times higher than the lowest ratio.
The differences in wDNELs seen in Table 3 and Figure 2 may be due to differences in the selection of dose descriptors as well as differences in dose modification and selected AFs. In order to more closely identify the cause for the differences, the relevant DNEL related information for the 20 substances was compiled from the ECHA database. Based on this information and the assumptions outlined in the methods section the most likely dose descriptor used by industry for wDNEL derivation was identified (Table 4) . For isopentyl acetate a full description of the wDNEL derivation was disseminated, including modification of dose descriptor. For the other substance fewer details were offered. Almost all, 21 out of 24 wDNEL entries (including the registered wDNEL for all cresol isomers) specified the most sensitive endpoint. For 15 wDNELs the registrants had specified the OAF. For three wDNELs the numerical value of the dose descriptor was listed, although for two it was not possible to identify that value from any of the available study summaries presented in the ECHA database. For nitrous oxide the DNEL related information specifies that a national OEL is used, but not which. For o-dichlorobenzene a reference is given to "other:VCI" without further explanation (Table 4) .
[ Table 4 ] Due to this lack of transparency, we were unable to identify the key studies used by industry for four wDNELs, although for the two styrene wDNELs a dose descriptor was stated in the DNEL related information. For six wDNELs we were unable to assess the identified dose descriptor in relation to the wDNEL because the DNEL related information did not include the value of the OAF. For three of the wDNELs the ratio between the identified dose descriptor and the registered wDNEL does not correspond to the stated OAF, regardless of whether or not we modify the identified dose descriptor as described in the ECHA guidance document. For the remaining twelve wDNELs the identified dose descriptors are consistent with the OAFs and registered wDNELs. Our judgement of consistency allows for some slight differences, e.g. due to conversion from ppm to mg/m 3 -which differs somewhat depending on the room temperature and rounding off.
[ Table 5] A comparison of the dose descriptors in Table 4 with those used by us for derivation of wDNELs indicates some overlap in the selection of leading effects. When combined with information about the year of the critical dose descriptors (Table 5) , the overlap in data and dose descriptor selection seems to be limited to one substance, dimethylamine. For another substance, 2-ethoxyethanol, the same study has been used (as identified by a full bibliographic reference in the ECHA database) but whereas the SCG cited a NOAEL of 37 mg/m 3 , the registrants cite this value as a LOAEL value. Also for γ-butyrolactone it seems that the REACH registrant selected the critical dose descriptor from the same study as us (based on publication year and information about study design, albeit not a full bibliographic reference), still the values of dose descriptors cited are different. Obviously, not only selection of critical study, be it due to time-related availability or judgment of reliability and relevance, but also the interpretation of the very same study may influence the dose descriptor.
With regards to time-related availability of studies, we found no relationship between difference in the age of the dose-descriptors used for derivation of wDNEL and the ratio between the registrants' wDNELs and our wDNELs. Further, there are no discernible trends for time difference between Swedish OEL setting and age of the critical dose descriptor and the ratio between wDNEL and OEL.
Comparing the default OAF for the dose descriptors identified in Table 4 with the OAFs listed in the DNEL related information, shows that for four wDNELs the registered OAF corresponds to the default values in the ECHA guidance document (Table 6 ). For one industry wDNEL, 2-ethoxyethanol, the registered OAF is much higher than the default value according to our interpretation of the ECHA guidance. The difference is a factor of six (225/37.5), which leads us to believe that a potential explanation could be the AF for duration of exposure which we set to 1 for developmental studies covering the relevant period of gestation. The default AF for subacute to chronic exposure is 6. For the other substances the default OAF is higher than the registered OAF. It should be noted that we have not been able to scrutinize any justifications for deviation from the defaults.
[ Table 6 ] DISCUSSION For the purpose of the present study, we compared registered wDNELs with Swedish OELs and for a subset of 20 different substances also with wDNELs derived by us. There is a notable variation in the registered wDNELs compared to the Swedish OELs. For a few substances the differences, or even a lack of difference, may be due to differences in the intended size fraction for particulates, as this is not specified for DNELs in the ECHA database. Another factor is that the Swedish OELs are pragmatic, and may hence not always be purely health-based, such as SCOEL recommendations for IOELVs are claimed to be. Pragmatic considerations would be expected to yield higher OELs compared to the healthbased wDNELs. Also, the Swedish OELs are derived over a period of close to 40 years, while REACH wDNELs can be assumed to have been derived for the registration deadlines in 2011 and 2013. Data availability could be one factor causing the differences, and judging from the general development of OELs as they have been revised over time this would also lead one to expect old Swedish OELs to be higher, or at least that the differences in general are larger for substances with an old Swedish OEL. This was however, not the case as the ratio between registered wDNEL and Swedish OEL varied in a constant manner over time (Figure 3 ).
When selecting substances for which we were to derive our own wDNELs, many were sorted out due to the lack of an identifiable threshold effect. Among these were substances that the available data was too scant, but also carcinogens and respiratory sensitisers. Fifty-eight substances were sorted out in this step, yet in previous steps it had been established that these also had a wDNEL available in the ECHA database. A registered wDNEL value implies the registrant has concluded that there is a threshold mode of action, and sufficient data available to identify a key dose descriptor. That many substances were sorted out from our study due to scant data at the time of the SCG's review is could be a sign of progress towards the aim of increased data availability. It could also be due to registrants' more extensive use of readacross or that DNELs may be derived on a poorer basis than the SCG customary accepts for identifying a critical effect for occupational exposure. However, for respiratory sensitisers and many carcinogens current knowledge does not suggest a threshold mode of action, and hence it seems likely many substances have DNEL values on an erroneous basis. This latter finding was also made by Püringer (2011) , who found that after the first registration deadline 293 substances had been registered as proven carcinogens, yet 21.8% of these also had a registered DNEL.
For the 20 substances we evaluated closer, there is a large discrepancy between our conclusions on wDNELs and the registered wDNELs derived by industry. In most cases it seems as we used a different dose descriptor in the wDNEL derivation than what was, to our best understanding, used by the industry registrant. Thus some of the differences between our wDNELs and the registered DNELs are due to selection of data and identification the leading effect. Registrants' key studies were in most cases more recently performed than the studies from which we selected our critical dose descriptor, but only for three wDNELs were the SCG documents older than the registrants' key studies (Table 5 ). Presumably many of these newer studies are not publicly available; again lack of the bibliographic references in the ECHA database makes it difficult to ascertain the publication status. With this access to data that cannot be found in the published literature the registrants are in the best position to derive the DNELs. However, these additional data have generally not been peer reviewed, and hence have not been subjected to the quality review that peer review entails.
Due to the lack of transparency, many times it was not possible to ascertain that we identified the dose descriptor and key study actually used by the registrants. Although we excluded registered wDNELs likely to be adapted from IOELVs, one possible confounding factor is that the wDNEL may in fact be based on a health-based OEL other than the IOELV. In our selection the wDNEL for nitrous oxide was, according to the DNEL related information, also a national OEL. As the use of national OELs is not mandatory to reveal in the DNEL related information, additional wDNELs in our selection may in fact be based on OELs rather than derived based on the data submitted for registration.
Selection of AFs plays a major role in explaining variability between standard setters, as is most likely also the case for many of the differences between the registrants' and our wDNELs. In the methods section we described a number of assumptions and simplifications that we had to make in order to derive our DNELs. Some of these assumptions may be questionable. For instance, we have always used an AF of 1 for quality of database and an AF of 3 for extrapolation from a LOAEL to a NOAEL although the text in the REACH guidance says that higher AFs may be used. The difference between the registered DNELs and our DNELs would obviously have been even larger, had we used AFs greater than 1 and 3, respectively. Thus it is evident that the large difference cannot be entirely due to the assumptions and simplifications we made to derive the wDNELs.
Regarding the quality of the database, ECHA recommends a default AF of 1. However, at present ECHA provides no quantitative advice regarding alternatives to the default. It should be kept in mind that low quality data can be handled in two opposite directions. One option is to assign a higher AF for data quality; this tends to overestimate the risk of adverse effects. A second option is to completely disregard studies of low quality. In some cases, of course depending on the study's results, such an approach may ignore findings that indicate adversity at low exposures and thus underestimate the risk.
On the other hand, a relatively high degree of conservatism, or caution, is built in in the DNEL derivation process by the selection of "most critical DNEL" for "leading healtheffects" that is selecting the dose descriptor and effect that leads to the lowest DNEL (ECHA, 2012). However, it remains to be investigated how the most critical DNEL is selected in the face of the reviewed effects. Our investigation shows that either the dose descriptors for wDNELs are not selected according to the principle of most critical DNEL (i.e. based on the effect leading to the lowest value); or the AFs applied are lower than indicated in the ECHA guidance and in some instances even below 1.
The discrepancies in selection of AFs, shown in the present study, leads to the questions on the sufficiency of the guidance document but also on the incentives for industry. A conflict of interest seems obvious as lower DNELs may lead to higher costs for risk management measures. This makes transparency even more important, with the limited information currently available in the ECHA database we cannot judge whether the deviation in AFs are scientifically justified or not. Disclosing the information on what is the most sensitive endpoint, the OAF after modification and what kind (e.g. NOAEL/LOAEL) of dose descriptor was used as a starting point is a clear improvement in this respect.
Regardless of the incentives, the way of presenting default ranges for AFs in the ECHA guidance (ECHA, 2010) is likely to cause inconsistent selection of AFs, maybe with a bias towards low values. As pointed out previously (Schenk and Johanson, 2011) ranges of default AFs are given in the text of the guidance document (ECHA, 2010) whereas only the lowest values of the ranges are given in the summary tables. For instance, the default AF for issues related to the reliability of the dose-response relationship, including extrapolation from LOAEL to NOAEL is specified as 1 in Table R .8-6 (ECHA 2010) . Meanwhile, for a LOAEL to NOAEL extrapolation the text suggests an AF "between 3 (as minimum/majority of cases) and 10 (as maximum exceptional cases)". Such ambiguities are likely to result in arbitrary choices of AFs. Thus one assessor, reading only the table, would apply an AF of 1 whereas another assessor, reading also the text, would apply an AF of 3, or perhaps even 10. Increased numerical guidance would probably be of benefit for the consistency of DNELs.
CONCLUSIONS
The comparison between industry's wDNELs and the Swedish OELs showed a large variability, industry's DNELs could be both significantly higher (up to 450 times) and significantly lower (up to 230 times) than the Swedish OELs. Nearly one fifth of the wDNELs were at least double the Swedish OEL, whereas one third of the wDNELs were half the Swedish OEL or lower. There was no correlation between the age of the Swedish OEL and the size of the ratio between DNEL and OEL, i.e. older OELs were not systematically higher than the recently set wDNELs.
Also comparing industry's wDNELs to our wDNELs yielded a large variability. However, our wDNELs were generally lower than both the corresponding Swedish OELs and industry wDNELs. In the present study we identified a number of plausible explanations for these discrepancies. Industry may choose an existing OEL as their wDNEL, select different data as basis for their evaluation, have different opinion on what is an adverse effect, or interpret the REACH guidance differently in regards to modification of dose descriptors and application of AFs. It seems to be common that registrants deviate markedly from the default AFs given by ECHA.
A limitation of our study is that, as a consequence of the study approach, the number of substances covered is low. This is to some extent counteracted by the diversity of substances; still, further efforts are needed to evaluate the scientific grounds for the registrants' evaluations. Furthermore, the scrutiny of the basis for DNELs is hampered by the lack of transparency of the ECHA database. The DNEL related information varied between substances, and only in one case did we encounter a fully transparent derivation, i.e. specifying the point of departure, how it was modified and which specific AFs were applied. In many cases bibliographic references were missing from the study summaries provided, making it very difficult to ascertain whether the SCG had cited the same data, and if so whether the evaluation of reliability and relevance differed. Another major issue related to transparency concerns the case of DNELs for particulates, the size fraction applicable for the DNEL is not specified in ECHA database. It may be the case that registrants use a specific, and relevant for the registrants' workplaces, size fraction in the DNEL derivation and in the corresponding exposure assessments towards identifying proper risk management measures. However, whether this is the case or not is not publicly disseminated in the ECHA database. Hence, we can conclude that the publicly available information needs to be further expanded, so that more -and preferably full-transparency is offered regarding the basis of the registered DNELs. The system with industry DNELs holds more value when every interested party is able to make an informed assessment about their derivation.
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